Using Bioimpedance-Based Technology for Early Detection of Cancer with Jared Bauer IONIQ Sciences

Jared Bauer is the CEO of IONIQ Sciences which is exploring new ways to detect cancer at an earlier stage using non-invasive bioimpedance-based technology. This approach is not looking for the presence of cancer cells but rather changes in the interstitial fluid. Using a low level of electric current, the IONIQ AI-enhanced technology can identify where in the body the cancer is. Jared explains, "It's a bioimpedance-based technology, and the way the system works is we inject a very low level of electrical current, not enough for you to feel. You can't even recognize that it's there. Still, we inject electrical current using DC power, direct current. If you just think physics 101, electricity 101, whatever you want to call it, DC power, the path of least resistance, and that electricity is going to go through the interstitial fluid. Then we pull that back out with an EKG electrode on the other side. And we're scanning that interstitial fluid over distances, allowing us to see that immune response." "When someone doesn't have cancer, the ions or that electricity is going to flow freely. When someone does have cancer, a malignancy is present, and we see that cytokine storm, the changes in the chemokines, and the changes in the protein matrix. All of the interstitial fluid gets jumbled up, and those ions don't move as smoothly through. So over the course of a 20-minute, non-invasive test, just electrical current, it's all digital, we pull 10,000-plus data points from our scan, and we analyze that using our proprietary algorithm to give you an answer of malignant or benign." #IONIQSciences #EarlyDetectionofCancer #Cancer #LungCancer #Bioimpedance #CancerScreening ioniqsciences.com  Download the transcript here